Host-directed therapies for tuberculosis

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 10, 2015, Pages

  Tobin, David M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALISPORIVIR; CC 3052; CIPEMASTAT; CORTICOSTEROID; DESIPRAMINE; DEXAMETHASONE; GEFITINIB; IBUPROFEN; IMATINIB; INTERLEUKIN 2; ISONIAZID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PIOGLITAZONE; PREDNISONE; ROSIGLITAZONE; THALIDOMIDE; TREPROSTINIL; UNCLASSIFIED DRUG; VITAMIN D; ZILEUTON; ANTIINFLAMMATORY AGENT; ICOSANOID; IMMUNOLOGIC FACTOR; MATRIX METALLOPROTEINASE; PROTEIN KINASE;

ANTIBIOTIC RESISTANCE; ARTICLE; AUTOPHAGY; CELL CULTURE; DRUG TARGETING; HOST DIRECTED THERAPY; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATION; LIPID METABOLISM; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; THERAPY; TUBERCULOSIS; TUBERCULOUS MENINGITIS; ANIMAL; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOPHAGY; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EICOSANOIDS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFLAMMATION; LIPID METABOLISM; MATRIX METALLOPROTEINASES; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASES; TUBERCULOSIS; VITAMIN D;

EID: 84943328511     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021196     Document Type: Article

References (133)

1. Abel L, El-Baghdadi J, Bousfiha AA, Casanova JL, Schurr E. 2014. Human genetics of tuberculosis: A long and winding road. Philos Trans R Soc Lond B Biol Sci 369: 20130428.
2. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR. 2009. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature 460: 98-102.
3. Almeida PE, Silva AR, Maya-Monteiro CM, Torocsik D, D'Avila H, Dezso B, Magalhaes KG, Castro-Faria-Neto HC, Nagy L, Bozza PT. 2009. Mycobacterium bovis bacillus Calmette-Guerin infection induces TLR2-dependent peroxisome proliferator-activated receptor γ expression and activation: Functions in inflammation, lipid metabolism, and pathogenesis. J Immunol 183: 1337-1345.
4. Arbiser JL,Moschella SL. 1995. Clofazimine: A review of its medical uses and mechanisms of action. J Am Acad Dermat 32: 241-247.
5. Bafica A, Scanga CA, Serhan C, Machado F,White S, Sher A, Aliberti J. 2005. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 115: 1601-1606.
6. Berry MP, Graham CM,McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J,Wilkinson RJ, et al. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973-977.
7. Bruns H, Stegelmann F, Fabri M, Dohner K, van Zandbergen G, Wagner M, Skinner M, Modlin RL, Stenger S. 2012. Abelson tyrosine kinase controls phagosomal acidification required for killing ofMycobacterium tuberculosis in human macrophages. J Immunol 189: 4069-4078.
8. Bryk R,Wu K, Raimundo BC, Boardman PE, Chao P, Conn GL, Anderson E, Cole JL, Duffy NP,Nathan C, et al. 2011. Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett 21: 4108-4114.
9. Canetti G. 1955. The tubercle bacillus in the pulmonary lesion of man: Histobacteriology and its bearing on the therapy of pulmonary tuberculosis, Springer, New York.
10. Casadevall A, Pirofski LA. 2003. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1: 17-24.
11. Castelnuovo B. 2010. A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa. Afr Health Sci 10: 320-324.
12. Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, Delgado-Vargas M, Timmins GS, Bhattacharya D, Yang H, et al. 2012. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci 109: E3168- E3176.
13. Chen M, Divangahi M, Gan H, Shin DS, Hong S, Lee DM, Serhan CN, Behar SM, Remold HG. 2008. Lipid mediators in innate immunity against tuberculosis: Opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 205: 2791-2801.
14. Chen CY, Yao S, Huang D, Wei H, Sicard H, Zeng G, Jomaa H, Larsen MH, Jacobs WR Jr,Wang R, et al. 2013. Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog 9: e1003501.
15. Claria J, Serhan CN. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci 92: 9475-9479.
16. Colangeli R, Arcus VL, Cursons RT, Ruthe A, Karalus N, Coley K, Manning SD, Kim S, Marchiano E, Alland D. 2014. Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans. PLoS ONE 9: e91024.
17. Condos R, Rom WN, Schluger NW. 1997. Treatment of multidrug-resistant pulmonary tuberculosis with interferon- γ via aerosol. Lancet 349: 1513-1515.
18. Corral LG, Kaplan G. 1999. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 58: I107-I113.
19. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR, Bothamley GH, Packe GE, et al. 2012. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci 109: 15449-15454.
20. Critchley JA, Young F, Orton L, Garner P. 2013. Corticosteroids for prevention of mortality in people with tuberculosis: A systematic reviewand meta-analysis. Lancet Infect Dis 13: 223-237.
21. D'Avila H,Melo RC, Parreira GG,Werneck-Barroso E, Castro-Faria-Neto HC, Bozza PT. 2006. Mycobacterium bovis bacillus Calmette-Guerin induces TLR2-mediated formation of lipid bodies: Intracellular domains for eicosanoid synthesis in vivo. J Immunol 176: 3087-3097.
22. Dawson R, Condos R, Tse D, Huie ML, Ress S, Tseng CH, Brauns C,Weiden M, Hoshino Y, Bateman E, et al. 2009. Immunomodulation with recombinant interferon-γ1b in pulmonary tuberculosis. PLoS ONE 4: e6984.
23. Desvignes L, Ernst JD. 2009. Interferon-γ-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 31: 974-985.
24. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. 2008. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: Pathogenesis, clinical manifestations and management. Drugs 68: 191-208.
25. Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM, Fortune S, Behar SM, Remold HG. 2009. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 10: 899-906.
26. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. 2010. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol 11: 751-758.
27. Dkhar HK, Nanduri R, Mahajan S, Dave S, Saini A, Somavarapu AK, Arora A, Parkesh R, Thakur KG, Mayilraj S, et al. 2014. Mycobacterium tuberculosis keto-mycolic acid and macrophage nuclear receptor TR4 modulate foamy biogenesis in granulomas: A case of a heterologous and noncanonical ligand-receptor pair. J Immunol 193: 295- 305.
28. Dorhoi A, Iannaccone M, Farinacci M, Fae KC, Schreiber J, Moura-Alves P, Nouailles G, Mollenkopf HJ, Oberbeck-Muller D, Jorg S, et al. 2013. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest 123: 4836-4848.
29. Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker NF, Saraiva L, Pedersen B, Mauri F, Lipman M, et al. 2011a. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 121: 1827-1833.
30. Elkington PT, D'Armiento JM, Friedland JS. 2011b. Tuberculosis immunopathology: The neglected role of extracellular matrix destruction. Sci Transl Med 3: 71ps76.
31. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, Mahdy A, Zeidan Y, Bielwaska A, Hannun YA, et al. 2006. New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 580: 4751-4756.
32. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, Cho SN,Via LE, Barry CE., 3rd. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137: 122-128.
33. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, Lee HM, Krutzik SR, Schenk M, Sieling PA, et al. 2011. Vitamin D is required for IFN-γ-mediated antimicrobial activity of human macrophages. Sci Transl Med 3: 104ra102.
34. Flynn JL. 2006. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 8: 1179-1188.
35. Ford CB, Lin PL, Chase MR, Shah RR, IartchoukO, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, et al. 2011. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43: 482-486.
36. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J, Lipsitch M, Fortune SM. 2013. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 45: 784-790.
37. Fukutomi Y,Maeda Y,Makino M. 2011. Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob Agents Chemother 55: 4000-4005.
38. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580.
39. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. 2010. Multidrug-resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis. Lancet 375: 1830-1843.
40. Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, McKinney JD, Bertozzi CR, Sassetti CM. 2012. Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem Biol 19: 218- 227.
41. Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trebucq A. 2013. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 188: 608-612.
42. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. 2004. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119: 753-766.
43. Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. 2000. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 84: 183-188.
44. Hawn TR, Matheson AI, Maley SN, Vandal O. 2013. Hostdirected therapeutics for tuberculosis: Canwe harness the host? Microbiol Mol Biol Rev 77: 608-627.
45. Hemmings FJ, Farhan M, Rowland J, Banken L, Jain R. 2001. Tolerability and pharmacokinetics of the collagenaseselective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology 40: 537-543.
46. Iannaccone M, Dorhoi A, Kaufmann SH. 2014. Host-directed therapy of tuberculosis: What is in it for microRNA? Expert Opin Ther Targets 18: 491-494.
47. Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N,Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, et al. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS ONE 8: e75245.
48. Jayaswal S, Kamal MA, Dua R, Gupta S,Majumdar T, Das G, Kumar D, Rao KV. 2010. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog 6: e1000839.
49. Johnson BJ, Bekker LG, Rickman R, Brown S, Lesser M, Ress S,Willcox P, Steyn L, Kaplan G. 1997. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: A comparison of two treatment regimens and placebo. Tuber Lung Dis 78: 195-203.
50. Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG, Jankus DD, Eisenach KD, Boom WH, Ellner JJ, et al. 2003. Randomized trial of adjunctive interleukin- 2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 168: 185-191.
51. Kaufmann SH, Dorhoi A. 2013. Inflammation in tuberculosis: Interactions, imbalances and interventions. Curr Opin Immunol 25: 441-449.
52. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI,Maeurer M. 2014. Progress in tuberculosis vaccine development and host-directed therapies-A state of the art review. Lancet Respir Med 2: 301-320.
53. Kim JH, Scialli AR. 2011. Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicol Sci 122: 1-6.
54. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A,WangW, Hsu FF,Wiehart U, et al. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2: 258-274.
55. Kim JJ, Lee HM, Shin DM, KimW, Yuk JM, Jin HS, Lee SH, Cha GH, Kim JM, Lee ZW, et al. 2012. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe 11: 457-468.
56. Kiss M, Czimmerer Z, Nagy L. 2013. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology. J Allergy Clin Immunol 132: 264-286.
57. Koh WJ, Kwon OJ, Suh GY, Chung MP, Kim H, Lee NY, Kim TS, Lee KS. 2004. Six-month therapy with aerosolized interferon-γ for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 19: 167-171.
58. Koo MS, Manca C, Yang G, O'Brien P, Sung N, Tsenova L, Subbian S, Fallows D,Muller G, Ehrt S, et al. 2011. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS ONE 6: e17091.
59. Krutzik SR, Hewison M, Liu PT, Robles JA, Stenger S, Adams JS, Modlin RL. 2008. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol 181: 7115-7120.
60. Kuijl C, Savage ND, Marsman M, Tuin AW, Janssen L, Egan DA, Ketema M, van den Nieuwendijk R, van den Eeden SJ, Geluk A, et al. 2007. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 450: 725-730.
61. Kumar D, Nath L, Kamal MA, Varshney A, Jain A, Singh S, Rao KV. 2010. Genome-wide analysis of the host intracellular network that regulates survival ofMycobacterium tuberculosis. Cell 140: 731-743.
62. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
63. MacMicking JD, Taylor GA, McKinney JD. 2003. Immune control of tuberculosis by IFN-γ-inducible LRG-47. Science 302: 654-659.
64. Mahajan S, Dkhar HK, Chandra V, Dave S, Nanduri R, Janmeja AK, Agrewala JN, Gupta P. 2012. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARγ and TR4 for survival. J Immunol 188: 5593-5603.
65. Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, Maiga MC, Lun S, Bishai WR. 2012. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE 7: e30749.
66. Maiga M, Ammerman NC, Maiga MC, Tounkara A, Siddiqui S, Polis M, Murphy R, Bishai WR. 2013. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 208: 512-519.
67. Marais S,Wilkinson RJ, Pepper DJ, Meintjes G. 2009. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 6: 162-171.
68. Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, Nawroly N, Packe GE, Davidson RN, Griffiths CJ,Wilkinson RJ. 2007. Neutrophil-mediated innate immune resistance tomycobacteria. J Clin Invest 117: 1988- 1994.
69. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN, et al. 2011. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: A double-blind randomised controlled trial. Lancet 377: 242-250.
70. Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P, Oland S, Gordon S, Sher A. 2011. Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35: 1023-1034.
71. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzalez J, Derrick SC, Shi R, Kumar NP, Wei W, et al. 2014. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511: 99-103.
72. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. 2002. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2002: CD000526.
73. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, WorodriaW, Elliott JH,MurdochD,Wilkinson RJ, Seyler C, et al. 2008. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516-523.
74. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G. 2010. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24: 2381-2390.
75. Misra UK, Kalita J, Nair PP. 2010. Role of aspirin in tuberculous meningitis: A randomized open label placebo controlled trial. J Neurol Sci 293: 12-17.
76. Morcos MM, Gabr AA, Samuel S, Kamel M, el Baz M, el Beshry M, Michail RR. 1998. Vitamin D administration to tuberculous children and its value. Boll Chim Farm 137: 157-164.
77. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, Bellingan G, Gilroy DW. 2009. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 183: 2089-2096.
78. Nandi B, Behar SM. 2011. Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection. J Exp Med 208: 2251-2262.
79. Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. 2011. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10: 475-485.
80. Nouailles G, Dorhoi A, Koch M, Zerrahn J, Weiner J, 3rd, Fae KC, Arrey F, Kuhlmann S, Bandermann S, LoeweD, et al. 2014. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest 124: 1268-1282.
81. Nursyam EW, Amin Z, Rumende CM. 2006. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones 38: 3-5.
82. Overall CM, Lopez-Otin C. 2002. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2: 657-672.
83. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR, Kramnik I. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434: 767-772.
84. Pandey AK, Sassetti CM. 2008. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci 105: 4376-4380.
85. Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, Suzuki H, Marais AD, Brombacher F. 2014. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 209: 754-763.
86. ParksWC, Wilson CL, Lopez-Boado YS. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4: 617-629.
87. Philips JA, Rubin EJ, Perrimon N. 2005. Drosophila RNAi screen reveals CD36 family member required for mycobacterial infection. Science 309: 1251-1253.
88. Podinovskaia M, Lee W, Caldwell S, Russell DG. 2013. Infection of macrophages with Mycobacterium tuberculosis induces global modifications to phagosomal function. Cell Microbiol 15: 843-859.
89. Prasad K, Singh MB. 2008. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008: CD002244.
90. Quarato G, D'Aprile A, Gavillet B, Vuagniaux G, Moradpour D, Capitanio N, Piccoli C. 2012. The cyclophilin inhibitor alisporivir prevents hepatitis C virusmediated mitochondrial dysfunction. Hepatology 55: 1333-1343.
91. Rajaram MV, Brooks MN,Morris JD, Torrelles JB, Azad AK, Schlesinger LS. 2010. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor γ linking mannose receptor recognition to regulation of immune responses. J Immunol 185: 929-942.
92. Rajaram MV, Ni B, Morris JD, Brooks MN, Carlson TK, Bakthavachalu B, Schoenberg DR, Torrelles JB, Schlesinger LS. 2011. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc Natl Acad Sci 108: 17408-17413.
93. Ramakrishnan L. 2012. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12: 352-366.
94. Rask-Andersen M, Masuram S, Schioth HB. 2014. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol 54: 9-26.
95. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. 2010. Statins and all-cause mortality in highrisk primary prevention: A meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 170: 1024-1031.
96. Reeves PM, Bommarius B, Lebeis S,McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, et al. 2005. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 11: 731-739.
97. Roca FJ, Ramakrishnan L. 2013. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 153: 521-534.
98. Rubinsztein DC, Codogno P, Levine B. 2012. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 11: 709-730.
99. Sacchettini JC, Rubin EJ, Freundlich JS. 2008. Drugs versus bugs: In pursuit of the persistent predatorMycobacterium tuberculosis. Nat Rev Microbiol 6: 41-52.
100. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. 1997. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 99: 226-231.
101. Schoeman JF, Springer P, Ravenscroft A, Donald PR, Bekker LG, van Rensburg AJ, Hanekom WA, Haslett PA, Kaplan G. 2000. Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role. J Child Neurol 15: 497-503.
102. Schoeman JF, Springer P, van Rensburg AJ, Swanevelder S, Hanekom WA, Haslett PA, Kaplan G. 2004. Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study. J Child Neurol 19: 250-257.
103. Schoeman JF, Janse van Rensburg A, Laubscher JA, Springer P. 2011. The role of aspirin in childhood tuberculous meningitis. J Child Neurol 26: 956-962.
104. Schwegmann A, Brombacher F. 2008. Host-directed drug targeting of factors hijacked by pathogens. Sci Signal 1: re8.
105. Shah NS,Wright A, Bai GH, Barrera L, Boulahbal F,Martin- Casabona N, Drobniewski F, Gilpin C, Havelkova M, Lepe R, et al. 2007. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13: 380- 387.
106. Shoji-Kawata S, Sumpter R, Leveno M, Campbell GR, Zou Z, Kinch L,Wilkins AD, Sun Q, Pallauf K, MacDuff D, et al. 2013. Identification of a candidate therapeutic autophagy- inducing peptide. Nature 494: 201-206.
107. Singh SB, Davis AS, Taylor GA, Deretic V. 2006. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 313: 1438-1441.
108. SinghV, Jamwal S, Jain R,Verma P, Gokhale R, RaoKV. 2012. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. Cell Host Microbe 12: 669-681.
109. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, Bray MA, Carpenter AE,Moore CB, Siddiqi N, et al. 2014. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog 10: e1003946.
110. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, Peixoto B, Fallows D, Dartois V, Muller G, Kaplan G. 2011a. Phosphodiesterase- 4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 7: e1002262.
111. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, Peixoto B, Fallows D, Zeldis JB, Muller G, Kaplan G. 2011b. Phosphodiesterase- 4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 179: 289-301.
112. Sundaramurthy V, Barsacchi R, Samusik N, Marsico G, Gilleron J, Kalaidzidis I, Meyenhofer F, Bickle M, Kalaidzidis Y, Zerial M. 2013. Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. Cell Host Microbe 13: 129-142.
113. Taylor JL, Hattle JM, Dreitz SA, Troudt JM, Izzo LS, Basaraba RJ, Orme IM, Matrisian LM, Izzo AA. 2006. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun 74: 6135-6144.
114. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, et al. 2004. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351: 1741-1751.
115. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J, British Infection S. 2009. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 59: 167-187.
116. Tobin DM, Vary JC Jr, Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge S, King MC, Hawn TR, et al. 2010. The lta4 h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140: 717-730.
117. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, et al. 2012. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148: 434- 446.
118. Ustianowski A, Shaffer R, Collin S,Wilkinson RJ, Davidson RN. 2005. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. J Infect 50: 432-437.
119. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. 2010. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat Rev Mol Cell Biol 11: 700-714.
120. Verway M, Bouttier M, Wang TT, Carrier M, Calderon M, An BS, Devemy E,McIntosh F, Divangahi M, Behr MA, et al. 2013. Vitamin D induces interleukin-1β expression: Paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathog 9: e1003407.
121. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. 2013. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 208: 199-202.
122. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. 2010. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327: 466-469.
123. Watson RO, Manzanillo PS, Cox JS. 2012. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 150: 803-815.
124. Wejse C, Olesen R, Rabna P, Kaestel P, Gustafson P, Aaby P, Andersen PL, Glerup H, Sodemann M. 2007. Serum 25- hydroxyvitamin D in aWest African population of tuberculosis patients and unmatched healthy controls. Am J Clin Nutr 86: 1376-1383.
125. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M. 2009. Vitamin D as supplementary treatment for tuberculosis: A doubleblind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 179: 843-850.
126. WHO. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva.
127. Wilkinson RJ. 2014. Host-directed therapies against tuberculosis. Lancet Respir Med 2: 85-87.
128. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A,Wright D, Latif M, Davidson RN. 2000. Influence of vitaminDdeficiency and vitaminDreceptor polymorphisms on tuberculosis among Gujarati Asians in west London: A case-control study. Lancet 355: 618-621.
129. Wu K, Koo J, Jiang X, Chen R, Cohen SN, Nathan C. 2012. Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R. PLoS ONE 7: e30512.
130. Yang CT, Cambier CJ, Davis JM, Hall CJ, Crosier PS, Ramakrishnan L. 2012. Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages. Cell Host Microbe 12: 301-312.
131. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo EK. 2009. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 6: 231-243.
132. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12: 388-404.
133. Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ. 2014. New antituberculosis drugs, regimens, and adjunct therapies: Needs, advances, and future prospects. Lancet Infect Dis 14: 327-340.